By Dani Kass ( February 26, 2016, 4:30 PM EST) -- The Federal Trade Commission on Friday said that for Hikma Pharmaceuticals PLC's $2.2 billion purchase of Boehringer's U.S. generics business to pass antitrust muster, the drugmaker would have to sell all rights to two of its generic drugs and marketing rights to a third....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.